XENE Stock Xenon Pharmaceuticals (XENE, $51.72) price may climb as it broke lower Bollinger Band on Jun 05, 2026
at Tickeron.com
This price move could be a signal that XENE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. A.I.dvisor backtested 44 similar cases where XENE's price broke its lower Bollinger Band, and of them led to a successful outcome. Odds of Success:
XENE in upward trend: price may jump up because it broke its lower Bollinger Band on June 05, 2026
XENE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 44 cases where XENE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XENE advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XENE as a result. In of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
XENE moved below its 50-day moving average on May 14, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for XENE crossed bearishly below the 50-day moving average on May 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XENE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for XENE entered a downward trend on June 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. XENE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.738) is normal, around the industry mean (19.817). P/E Ratio (0.000) is within average values for comparable stocks, (36.300). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.691). XENE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (588.235) is also within normal values, averaging (355.038).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.